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Self-monitoringPurpose: Medication nonadherence is one of the most important reasons for treatment failure in patients with
epilepsy. The present study investigated the effectiveness of a multicomponent intervention to improve adher-
ence to antiepileptic drug (AED) medication in patients with epilepsy.
Methods: In a prospective, randomizedmulticenter trial, three sessions of face-to-face motivational interviewing
(MI) in combination with complementary behavior change techniques were compared with standard care. Mo-
tivational interviewing prompted change talk and self-motivated statements from the patients, planning their
own medication intake regimen and also identifying and overcoming barriers that may prevent adherence. Par-
ticipants were provided with calendars to self-monitor their medication taking behavior. A family member and
the health-care teamwere invited to attend the last session of MI in order to improve the collaboration and com-
munication between patients, their caregiver or family member, and their health-care provider. At baseline and
6-month follow-up, psychosocial variables and medical adherence were assessed.
Results: In total, 275 participants were included in the study. Comparedwith the active control group, patients in
the intervention group reported signiﬁcantly highermedication adherence, aswell as stronger intention andper-
ceptions of control for taking medication regularly. The intervention group also reported higher levels of action
planning, coping planning, self-monitoring, and lower medication concerns.
Conclusions: This study shows thatMI can be effective in clinical practice to improvemedication adherence in pa-
tients with epilepsy. It also provides evidence that combining volitional interventions, including action planning,
coping planning, and self-monitoring with motivational interviewing can promote the effectiveness of the med-
ical treatments for epilepsy by improving adherence.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Epilepsy is oneof themost commonneurological disorders,with 4 to
10 in every 1000 people affected worldwide. The overall incidence of
epilepsy is around 50 per 100,000 people per year (range: 40 to 70
per 100,000 people per year) in industrialized countries and 100 to
190 per 100,000 people per year in developing countries [1]. In Iran,s, antiepileptic drugs; MARS,
edications Questionnaire; PBC,
edical Sciences, Qazvin, Iran.
r@qums.ac.ir (A.H. Pakpour).the prevalence of epilepsy has been estimated to be 18 per 1000 people
in the population [2].
Approximately 60% of patients with epilepsy could have full control
over their seizures with antiepileptic drugs (AEDs) if they took their
medication as prescribed [3]. However, nonadherence is one of the
most important reasons for treatment failure in these patients [4], as
30% to 50% of adultswith epilepsy adhere poorly to their AED treatment
schedules [5–9]. However, continuous objective measures suggest even
higher rates of nonadherence. For example, two studies using the Med-
ical Events Monitoring System (MEMS)—a pill bottle with an electronic
cap that records each time the bottle is opened—found that 76% of doses
were taken overall [10], and 48% of patients took one-third or fewer of
the prescribed AED doses [11].
Poor adherence affects important treatment outcomes such as num-
bers of hospital admissions, inpatient treatment days, emergency room
134 A.H. Pakpour et al. / Epilepsy & Behavior 52 (2015) 133–142visits, and health-care costs [12,13]. Nonadherent patients report more
uncontrolled seizures leading to greater epilepsy-related morbidity and
mortality compared with adherent patients. In addition, nonadherence
reduces treatment beneﬁts [14] and can bias assessment of the efﬁcacy
of these treatments [15,16].
Medication treatment for epilepsy and other chronic diseases
requires patients to merge regimens into daily routines [17]. Although
educating patients with epilepsy about medication regimens is critical
to treatment [6], additional factors such as sociodemographics or beliefs
about epilepsy and medication use are likely to inﬂuence treatment
adherence [18].
Nonadherence can be either intentional, due to a patient's own
choice, or nonintentional, due to forgetting or misunderstanding the
prescription and recommendations [19]. According to a Cochrane re-
view [19], behavior change interventions designed to increase medica-
tion adherence include simplifying the dosage regimen, combining
detailed instructions with counseling, increasing follow-up, sending
out reminders, and the use of self-monitoring, rewards, motivational
group sessions, and psychological therapy. The review also suggested
that education and counseling were effective strategies and behavioralN=137
Drop-outs (n=1)
Lost to follow-up 
(n=1)
Active comparator 
(n=138)
All available data 
Allocation
Post Intervention
1 month follow up
6 months 
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Fig. 1. CONSORT trinterventions including reminders and implementation intentions had
evidence of efﬁcacy in patients with epilepsy.
Most behavior change interventions contain educational and behav-
ioral techniques to improvemedical adherence and are usually based on
the assumption that participants are motivated to change [20]. Howev-
er, interventions that take a prescriptive, educational approachmay also
increase resistance among participants who are not intending to change
[21,22]. Motivation to adhere to epilepsymedications has received little
research attention.
Motivational interviewing (MI) is a patient-centered clinical strate-
gy that focuses on self-efﬁcacy and personal attitudes towards behavior
change. It aims to help individuals solve their ambivalence about change
and boost their intrinsic motivation [23,24]. It assesses a client's ‘readi-
ness’ to change and attempts to enhance motivation for behavior
change [25]. It encourages the patient to compare the pros and cons of
change and helps in the decision-making prior to education and self-
regulatory interventions by enhancing intrinsic motivation [20].
In one study on improving medication adherence in patients with
epilepsy, Dilorio et al. [26] provided 5MI sessions, of which the ﬁrst ses-
sion was face to face and the following four sessions were administeredAssessed for eligibility
N=300
Enrollment
N=275
Baseline assessment 
Randomization
Intervention
(n=137)
Lost to follow-up 
(n=3)
N=134
Drop-outs (n=3)
were analyzed: Intention to treat analysis
ial ﬂow chart.
Table 1
Demographic and clinical characteristics of the eligible subjects in intervention and active
comparator control groups.
Active comparator
(n = 138)
Intervention
(n = 137)
p-Value
Age (years)
Mean (SD) 39.86 (15.01) 41.37 (16.25) 0.40
Sex 0.70
Male 89 (67.2%) 92 (67.2%)
Female 49 (35.5%) 45 (32.8%)
Marital status 0.50
Single 62 (44.9%) 63 (46.0%)
Married 66 (47.8%) 59 (43.1%)
Divorced/widowed 10 (7.2%) 15 (10.9%)
Education (years)
Mean (SD) 7.12 (3.81) 7.03 (4.19) 0.39
Family income ($) 0.62
High (N1000$) 38 (27.5%) 40 (29.2%)
Intermediate (500–1000$) 72 (52.2%) 64 (46.7%)
Low (b500$) 28 (20.3%) 33 (24.1%)
Occupational status 0.59
Employed 43 (31.2%) 38 (27.7%)
Unemployed 95 (68.8%) 99 (72.3%)
Time since diagnosis (years)
Mean (SD) 15.27 (7.38) 14.88 (7.02) 0.37
Treatment regimen 0.59
Monotherapy 101 (73.2%) 37 (26.8%)
Polytherapy 96 (70.1%) 41 (29.9%)
Epilepsy type 0.56
Idiopathic 60 (43.5%) 55 (40.1%)
Cryptogenic 38 (27.5%) 34 (24.8%)
Symptomatic 40 (29.0%) 48 (35.0%)
Seizure type 0.91
Focal 64 (46.4%) 60 (43.8%)
Generalized (convulsions) 39 (28.3%) 38 (27.7%)
Absence 30 (21.7%) 32 (23.4%)
Unknown 5 (3.6%) 7 (5.1%)
Note. SD = standard deviation.
Table 2
The Motivational Interviewing Treatment Integrity (MITI) global measures, behavior
counts, and summary scores.
Measurers Mean ± SD Minimum Maximum
Global measures
Evocation 3.99 (0.65) 2 5
Collaboration 4.28 (0.43) 2 5
Autonomy/support 4.11 (0.55) 1 5
Direction 4.23 (0.67) 2 5
Empathy 4.64 (0.53) 1 5
Behavior counts
Giving information 0.31 (0.41) 0
MI—adherent 5.86 (2.98) 1 17
MI—nonadherent 0.91 (1.01) 0 5
Closed questions 13.21 (8.16) 1 31
Open questions 8.38 (4.42) 0 28
Simple reﬂections 11.82 (7.34) 0 48
Complex reﬂections 10.62 (6.03) 2 30
Summary scores
Global spirit rating 4.14 (0.51) 2.19 4.69
Percent complex reﬂections 52.89 (18.12) 10.83 100.00
Percent open questions 61.49 (16.30) 20.17 100.00
Reﬂection-to-question ratio 2.67 (2.73) 0.43 18.19
Percent MI adherent 98.07 (6.88) 50.00 100.00
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the study. Despite the scarcity of research on implementing MI to im-
prove medical adherence in patients with epilepsy, MI has been used
for medication adherence in patient populations with various other
medical problems to attempt to resolve ambivalence about medication
use and increase medication adherence behaviors [27]. For example,
in a study on patients with bipolar disorder, one face-to-face MI session
and two follow-ups of MI interventions by phone call were delivered by
psychiatric nurse practitioners, which was shown to be an effective
treatment approach to improve medication adherence [27].
In the present study, we tested whether amulticomponent interven-
tion to improve adherence to medication could lead to better adherence
to AEDs in patients with epilepsy. The intervention, which included mo-
tivational interviewing as a core element and included a combination of
related and supplementary behavior change techniques [28], was com-
pared with standard care [29] in a randomized controlled trial design.
We hypothesized that the active multicomponent intervention would
lead to better medication adherence compared with standard care at
the follow-up measurement points 3 and 6 months following delivery
of the intervention.
2. Experimental procedures
2.1. Design
The studydesignwas a prospective, randomized (1:1 allocation), dou-
ble blind, multicenter trial among patients with epilepsy. Patients were
recruited from 8 neurologic clinics from Qazvin (n = 2) and Tehran
(n=6). The study included two arms, a motivational interviewing inter-
vention and an active standard care comparator. The protocol was ap-
proved by the Medical Sciences ethics committee of Qazvin University
(February 2014) andwas registered onClinicalTrials.gov (NCT02165306).
2.2. Participants
The patients were recruited nonselectively and consecutively during
the period from June 2014 until February 2015. To be eligible for partic-
ipation, patients had to: (a) have a diagnosis of epilepsy according to the
International League Against Epilepsy criteria, (b) be aged 18 years or
over, (c) have independence in daily living activities or be responsible
for taking their medications, and (d) be prescribed AEDs. Patients
were excluded from the study if: (a) they had a presence of a rapidly
progressing neurological or medical disorder, (b) they were not pre-
scribed AEDs, (c) they had a diagnosis of an intellectual disability,
(d) they had major cognitive impairment (as assessed by the mini–
mental state examination b23), or (e) they were not able to read and
write Persian.
2.3. Motivational interviewing intervention
TheMI interventionwas amultifaceted program targeting improved
medication adherence behavior and clinical outcomes in patients with
epilepsy. Three weekly face-to-face sessions were performed to im-
provemedication adherence [24,30,31]. TheMI sessionswere delivered
individually by a male health psychologist with 10 years of experience
working with medication adherence in patients with chronic diseases
and 60 h of training of MI in Qazvin and Tehran. During the sessions,
the patientswere encouraged to express their experiences, values, read-
iness, and conﬁdence for the behavior change. All sessions were held in
a private and quiet settingwithin a neurologic clinic. Each session lasted
for 40 to 60 min. The MI techniques employed to resolve barriers and
encourage patients to take medications regularly were open-ended
questions, afﬁrmations, reﬂective statements, and summaries to elicit
change talk.
The sessions were conducted in four phases. The facilitator ﬁrst de-
scribed the aims of the session, and the patient's motivation andconﬁdence in relation to medication adherence were assessed. In the
second phase, the patients were encouraged to express their concerns
and barriers about taking medication regularly. The reasons for the re-
ported levels ofmotivation and conﬁdencewere explored, and the facil-
itator elicited self-motivational statements to foster motivation for
medication adherence. If appropriate, patients were invited to consider
Table 3
Means and standard deviations of all outcome measures in control and intervention groups at baseline and follow-ups.
Variable Group Baseline Month 3 Month 6
BMQ necessary Control 16.74 (2.11) 16.67 (2.15) 16.29 (2.04)
Intervention 16.41 (2.27) 19.32 (2.86) 19.26 (2.32)
BMQ concern Control 12.35 (2.13) 12.92 (1.87) 12.80 (2.07)
Intervention 12.89 (2.62) 9.71 (2.51) 9.73 (2.17)
BMQ-necessity minus concerns Control 4.39 (2.11) 3.75 (2.08) 3.49 (2.01)
Intervention 3.52 (2.37) 9.61 (2.61) 9.53 (2.18)
LSSS Control 57.87 (21.76) 58.09 (21.75) 60.04 (23.42)
Intervention 54.62 (22.93) 47.24 (17.41) 42.65 (17.85)
Seizure worry Control 57.47 (21.36) 56.67 (12.31) 55.03 (12.87)
Intervention 56.82 (18.48) 64.00 (19.95) 69.92 (11.41)
Overall quality of life Control 52.85 (17.98) 52.71 (17.97) 52.25 (17.21)
Intervention 53.75 (19.52) 58.39 (13.04) 62.67 (14.51)
Emotional well-being Control 55.03 (18.96) 53.91 (16.85) 52.62 (17.79)
Intervention 52.44 (15.08) 64.12 (17.38) 67.86 (17.43)
Energy/fatigue Control 50.57 (24.42) 49.42 (14.27) 48.14 (14.56)
Intervention 52.01 (15.03) 57.03 (16.13) 62.28 (1721)
Cognitive functioning Control 50.35 (11.33) 47.42 (11.82) 46.03 (12.87)
Intervention 48.67 (11.80) 56.58 (12.01) 59.92 (11.41)
Medication effects Control 55.01 (20.81) 54.64 (11.07) 53.57 (11.39)
Intervention 52.20 (18.91) 62.91 (19.68) 64.86 (19.23)
Social functioning Control 56.05 (15.66) 55.50 (15.84) 54.78 (16.42)
Intervention 58.42 (16.61) 67.03 (16.41) 70.17 (17.41)
Overall score Control 57.43 (14.35) 56.01 (12.12) 55.50 (11.77)
Intervention 55.75 (14.66) 62.14 (13.21) 65.57 (14.09)
Perceived behavioral control Control 2.53 (0.86) 2.54 (0.87) 2.49 (0.80)
Intervention 2.49 (0.79) 2.62 (0.72) 2.61 (0.85)
Intention Control 2.36 (0.92) 2.34 (0.97) 2.27 (0.87)
Intervention 2.39 (0.88) 2.72 (0.99) 2.73 (0.95)
Self-monitoring Control 1.56 (0.65) 1.51 (0.76) 1.49 (0.89)
Intervention 1.50 (0.53) 1.75 (0.71) 1.76 (0.68)
Action planning Control 2.08 (0.78) 2.03 (0.78) 1.92 (0.72)
Intervention 2.11 (0.66) 2.31 (0.69) 2.30 (0.85)
Coping planning Control 1.95 (0.48) 1.93 (0.54) 1.89 (0.52)
Intervention 1.96 (0.43) 2.34 (0.87) 2.32 (0.90)
Self-report Behavioural Automaticity Index Control 1.44 (0.54) 1.40 (0.51) 1.35 (0.49)
Intervention 1.39 (0.46) 1.63 (0.58) 1.64 (0.56)
MARS Control 16.34 (4.84) 16.07 (3.69) 15.98 (3.65)
Intervention 15.67 (3.47) 18.57 (2.21) 18.61 (2.86)
Note. BMQ= Beliefs about Medications Questionnaire, LSSS = Liverpool Seizure Severity Scale, MARS =Medication Adherence Report Scale.
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and were prompted to ﬁnd ways for overcoming recognized barriers.
The need to maintain medication adherence behavior was reinforced
by the facilitator for those patients without any perceived barriers. In
the third phase, the pros and cons of medication adherence behavior
were discussed. The patients were encouraged to think about the possi-
ble future situations in relation to medication adherence. Furthermore,
the facilitator and patients collaboratively identiﬁed a number of actions
for plan behavior change. Participants were encouraged to list those
values thatmight be helpful formedication adherence behavior. The pa-
tients also selected their top 3 values and expressed their reason for
selecting them. Patients were then invited to create a personal action
plan for their actions by specifying where, when, how, and how often
they would take medications (action planning), as speciﬁed in Michie
et al.'s Behavior Change Technique (BCT) Taxonomy [28]. In addition
to this, the patients were encouraged to identify the barriers that
might interfere with the implementation of their medication adherence
plans (barrier identiﬁcation/problem solving/coping planning) and to
specify how to overcome them [28]. Finally, in the fourth phase, patients
received a self-monitoring task and a drug diary calendar to help them
stick to their plans. This is described as ‘Prompt self-monitoring of be-
haviours’ in the BCT Taxonomy [28]. The patients were asked to com-
plete the calendar regularly.
The health-care team, including all GPs and nurses and the patient's
family member(s), also received one MI intervention session following
the same procedure as for patients. The following issues were discussed
separately between health-care providers and patients' familymembers: the importance of medication adherence in patients, moni-
toring medication use among patient, the importance of patients–doc-
tor collaboration in developing treatment regimes, allowing patients
to describe actual drug taking behavior, and making drug regimens
less complex, whenever possible.
2.4. MI integrity/ﬁdelity
In order to ensure the MI sessions were implemented as intended
and adequately, integrity and ﬁdelity were evaluated. The Motivational
Interview Treatment Integrity (MITI) scale was used to assess integrity
to MI in the intervention group [32]. Two trained independent evalua-
tors randomly selected 25% of interviews for scoring. The MI integrity
was assessed via the global scores and the behavior counts. The global
scores have ﬁve variables (i.e., empathy, evocation, collaboration,
autonomy/support, and direction) while behavior counts have eight
verbal variables (i.e., giving information, asking open-ended and
closed-ended questions, providing simple and complex reﬂections,
and making other statements categorized as MI adherent or not). The
session's MI ﬁdelity was determined through comparison with recom-
mended standards for global scores, and ratios were calculated [32].
2.5. Standard care (SC)
All participants in both groups received standard care consistent
with ‘treatment as usual’ for patients with epilepsy. This included a
one-time session of brief advice to use medications regularly lasting
Table 4
Cross-tabulation of concentration–dose ratio and time in study groups.
Time 1 Time 2 Time 3
Concentration–dose ratio Concentration–dose ratio Concentration–dose ratio
Within reference range
or higher, n (%)
Low or not
detectable, n (%)
Within reference range
or higher, n (%)
Low or not
detectable, n (%)
Within reference range
or higher, n (%)
Low or not
detectable, n (%)
Active comparator 61 (44.2%) 77 (55.8%) 57 (41.3%) 81 (58.7%) 52 (38.0%) 85 (62.0%)
Intervention 55 (40.1%) 82 (59.9%) 75 (55.1%) 61 (44.9%) 80 (59.7%) 54 (40.3%)
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ically discussed in these short sessions include coexisting diseases, the
history of drug use, current disease, and advice about the health risks
of irregular medication use. According to the BCT taxonomy, this
would be described as the behavior change technique of providing
information on consequences of behavior in general and also for the
individual [28].2.6. Sample size
The aim of this study was to assess whether the multimodal behav-
ioral intervention would be superior to routine counseling for patients
with epilepsy in improving medication adherence. Based on our main
outcome score (Medication Adherence Self Report Scale [MARS]), sam-
ple size was determined based on detecting a small effect (d= 0.34) on
MARS change scores with a power of 0.85 at p b 0.05 [33]. The required
sample size was 128 participants per condition, assuming that 10% of
the patients would be excluded from the analysis due to study attrition.2.7. Randomization
All participants gave their written informed consent prior to partici-
pation. All eligible participants who agreed to be included in the study
completed the baselinemeasures. Afterwards, an independent research-
er who was not involved in the study randomly allocated the patients
into either the intervention or active comparator groups. Randomization
was performed using a computer-generated code based on random
number sequence with stratiﬁcation by the study sites.2.8. Measures
The primary outcomeswere adherence to prescribed AEDs, assessed
with the serum level and the Medication Adherence Report Scale
(MARS).Table 5
The logistic regression model predicting serum level in study groups.2.8.1. Demographics
Demographic variables assessed included age, gender, monthly fam-
ily income, marital status, educational status, occupational status, med-
ication regimen, age of onset of epilepsy, epilepsy diagnosis duration,
epilepsy type, and seizure type.Variables Month Serum level
OR (CI) p-Value
Group (intervention vs. control) 1.11 (0.69–1.78) 0.64
Month 3 1.12 (0.70–1.79) 0.62
Intervention vs. control 3 1.35 (1.07–1.71) 0.03
Month 6 1.31 (0.82–2.10) 0.27
Intervention vs. control 6 2.81 (1.44–5.47) 0.002
Age 1.01 (1.00–1.02) 0.04
Gender (male) 1.12 (0.82–1.51) 0.46
Medication dosing regimens (monotherapy) 0.76 (0.45–1.29) 0.27
Time since seizure 1.01 (0.98–1.03) 0.49
Intercept 0.97 (0.63–1.49) 0.892.8.2. The Medication Adherence Report Scale (MARS)
The MARS is composed of ﬁve items measured on a ﬁve-point Likert
scale ranging from 1 (always) to 5 (never). This scale can be split into
two scores: nonintentional nonadherence (i.e., item1: forgetting, possible
range: 1–5) and intentional nonadherence (i.e., items 2–5, possible range:
4–20). In addition to this, the total score of the MARS was computed via
summing all 5 items (ranging from 5–25). Higher scores indicate higher
adherence to medication. The MARS has been used widely in patients
with neurologic disorders including epilepsy, and the Persian version
has been found to be highly valid and reliable [34].2.8.3. Serum level
Serum levels of antiepileptic drugs were assessed using a third gen-
eration of ﬂuorescence microparticle enzyme immunoassay (MEIA)
(Abbott Axsym®, Abbott Laboratories, Abbott Park, IL, USA). All blood
samples were taken just before the next usual dose of drug. The thera-
peutic ranges of AEDs have been reported elsewhere [35]. In order to
allow cross comparisons between the study groups, serum concentra-
tion–dose ratio was assessed by dividing the measured serum concen-
tration of AEDs (in lmol/L) by the total daily dose (in mg) taken by the
patient at that time. Serum levels were categorized into two categories
(according to the reference ranges for the laboratory of each AED) in-
cluding “low or not detectable” (i.e., nonadherent) and “within refer-
ence range or higher” (i.e., adherent).2.8.4. Beliefs about medications
Patient's beliefs about medication use were assessed by the Beliefs
about Medications Questionnaire (BMQ) [36]. The BMQ has two parts
including speciﬁc and general beliefs. We only assessed speciﬁc beliefs
in line with evidence showing that speciﬁc beliefs are associated with
medication adherence, whereas general beliefs are not. The BMQ specif-
ic has two subscales including necessity of and concern about medica-
tion adherence. Each subscale contains ﬁve questions, and responses
are scored on aﬁve-point Likert scale ranging from1 (strongly disagree)
to 5 (strongly agree). Total scores of each subscale could be computed
by summing all items, and scores ranged from 5 to 25. Higher scores
in necessity indicate stronger patient's belief about the importance of
taking their medication, while higher scores in concern indicate higher
patientworries and concern about taking theirmedications. The Persian
version of the BMQ has been tested in patients with type 2 diabetes and
showed good validity and reliability [37].2.8.5. Perceived behavioral control (PBC)
Perceived behavioral control was measured using four items
adapted from previous research [34]. The participants rated their re-
sponses on a ﬁve-point Likert scale from 1 (difﬁcult) to 5 (easy)
(e.g., “for me to take regular medication in the future is…”). Internal
consistency for this scale was acceptable (α= 0.93).
Table 6
Multiple linear regressionmodels predicting beliefs aboutmedicines, intention, perceived behavioral control, self-monitoring, action planning, copingplanning, andmedication adherence
behavior.
Variable Month BMQ speciﬁc necessity BMQ speciﬁc concerns PBC SM
Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value
Group (intervention vs. control) 2.90 (0.50) b0.001 −3.73 (0.57) b0.001 0.70 (0.14) b0.001 0.68 (0.12) b0.001
Month 3 1.79 (0.26) b0.001 −3.48 (0.34) b0.001 0.35 (0.07) b0.001 0.45 (0.06) b0.001
Intervention vs. control 3 3.15 (0.40) b0.001 −4.03 (0.48) b0.001 0.76 (0.11) b0.001 0.70 (0.08) b0.001
Month 6 2.70 (0.28) b0.001 −2.37 (0.29) b0.001 0.19 (0.07) b0.009 0.16 (0.06) 0.008
Intervention vs. control 6 2.17 (0.37) b0.001 −2.49 (0.41) b0.001 0.60 (0.10) b0.001 0.40 (0.08) b0.001
Age −0.01 (0.01) 0.19 0.07 (0.01) b0.001 −0.001 (0.003) 0.17 −0.01 (0.002) b0.001
Gender (male) −0.07 (0.04) 0.11 1.22 (0.43) 0.005 −0.20 (0.10) 0.04 0.20 (0.08) 0.01
Medication dosing regimens (monotherapy) −0.07 (0.04) 0.10 0.06 (0.05) 0.29 0.29 (0.11) 0.008 −0.01 (0.01) 0.24
Time since seizure −1.24 (0.37) 0.01 0.76 (0.47) 0.11 −0.05 (0.01) 0.006 −0.26 (0.08) 0.002
Intercept 17.25 (0.63) b0.001 17.61 (0.77) b0.001 4.01 (0.18) b0.001 4.09 (0.19) b0.001
Note. BMQ= Beliefs about Medications Questionnaire, PBC= perceived behavioral control, SM= self-monitoring, INT= behavioral intention, AP= action planning, CP= coping plan-
ning, BEH =medication adherence behavior, BA = behavioral automaticity.
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Intention to adhere to medication was assessed by ﬁve items
adapted from previous research [34]. An example item was “I intend
to take regular medication in the future”. These items were measured
on a ﬁve-point scale anchored by completely disagree (1) and
completely agree (5). Internal consistency analysis indicated that the
measure had adequate reliability (α= 0.86).
2.8.7. Self-monitoring
Self-monitoring was measured by three items adapted from previ-
ous research [38] (e.g., “During the last week, I have consistently moni-
toredwhen to takemymedications”, scored not at all true (1) to exactly
true (5)). Cronbach's α for the scale was 0.81 indicating acceptable
reliability.
2.8.8. Action planning
Action planning was assessed using four items with a stem: “I have
made a detailed plan regarding” followed by “(a) when to take medica-
tion”, “(b)where to takemedication”, “(c) how often to takemedication”,
and “(d) how to take medication”. All responses were rated on a ﬁve-
point Likert scale (1 = completely disagree, 5 = completely agree) [34].
The four items had high internal consistency (α= 0.92).
2.8.9. Coping planning
Coping planning was assessed by four items with a stem “I have
made a detailed plan regarding” followed by “(a) what to do if some-
thing interferes”, “(b)what to do if I forgot it”, “(c) how tomotivatemy-
self if I don't feel like it”, and “(d) how to prevent being distracted” [34].
All items were scored on ﬁve-point Likert scales ranging from 1
(completely disagree) to 5 (completely agree). The four items formed
an internally reliable scale (α= 0.92).
2.8.10. Behavioral automaticity
Behavioral automaticity was assessed using the Self-Report Behav-
ioural Automaticity Index (SRBAI). The SRBAI has four items which as-
sess automaticity of behavior. This scale has a stem “Behavior X
(e.g., medication adherence) is something…” followed by (a) “I do auto-
matically”, (b) “I do without having to consciously remember”, (c) “I do
without thinking”, and (d) “I start doingbefore I realize I'mdoing it”. Re-
spondents were asked to indicate the extent to which they agreed on a
ﬁve-point Likert scale ranging from 1 (disagree) to 5 (agree). The
Persian/Iranian version of the SRBAI has been adopted in an indepen-
dent study on patients with epilepsy. Therewas no difference to the En-
glish version. Moreover, the Iranian version of the SRBAI showed good
psychometric properties with an adult clinical population. In order to
ease comparison, a ﬁve-point Likert scale was employed.2.8.11. Liverpool Seizure Severity Scale (LSSS)
The LSSS is a self-report measure which assesses the severity of a
patient's seizures during the past 4 weeks [39]. It contains 12 items
that are scored on a Likert scale. Patients who had no seizure for
4weeks prior to the study score a “zero”while those patientswho failed
to answer four ormore question of the LSSSwere regarded as “missing”.
Individual scores ranged from 0 to 100 with higher scores indicating
worsening seizure severity. The Persian version of the LSSS had been
translated and culturally adapted prior to the study. The Persian version
of the LSSS has been found to be a valid and reliable tool in quantifying
seizure severity of patients with epilepsy and detecting changes in sei-
zure severity over time.
2.8.12. Health-related quality of life
Health-related quality of life in patients with epilepsy was assessed
using a standard tool, the Quality of Life in Epilepsy—31 inventory
(QOLIE-31) [40]. The QOLIE-31 is a self-reported questionnaire with
31 itemswhich cover seven dimensions including seizureworry, overall
quality of life, emotional well-being, energy–fatigue, cognitive function-
ing, medication effects, and social function. All responses ranged from 0
to 100 with higher scores indicating better quality of life. The overall
score of the QOLIE-31 could be computed by weighting and summing
seven dimension scores. The Persian version of the QOLIE-31 was
found to be a reliable measure to assess health-related quality of life
in patients with epilepsy [41].
2.9. Statistical analysis
Participant characteristics were summarized using descriptive statis-
tics (mean, standard deviation, frequency). To ensure the equivalence
of groups at baseline in terms of clinical and demographic variables, inde-
pendent t-test for continuous variables and chi-square tests for categori-
cal variables were performed. The magnitude of change over time across
study groups was examined by linear mixed models (PROCMIXED) for
continuous outcome variables controlling for age, gender, number of
medications, and time since seizure. Random effects included study cen-
ters andparticipant number.Mixedmodeling is an appropriate technique
for unequal numbers of participants at baseline and follow-up. In this
analysis, two between-participant effects (between groups and between
participants within groups) and three within-participant effects (be-
tween times, group by time interactions, and random variation) were in-
cluded. In this case, a series of separate linear mixed models were
evaluated. The analyses were applied in accordance to the intention-to-
treat principle. The method of estimation was maximum likelihood
with unstructured covariance. All tests and p-values were adjusted for
multiple comparisons using the Benjamini–Hochberg procedure. As
serum levelwas a binary outcome, a logisticmixedmodelwas conducted
Table 6
Multiple linear regressionmodels predicting beliefs aboutmedicines, intention, perceived behavioral control, self-monitoring, action planning, copingplanning, andmedication adherence
behavior.
INT AP CP BEH BA
Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value
0.53 (0.14) b0.001 0.39 (0.10) b0.001 0.52 (0.14) b0.001 4.05 (0.60) b0.001 0.64 (0.12) b0.001
0.38 (0.05) b0.001 0.23 (0.05) b0.001 0.45 (0.06) b0.001 3.25 (0.43) b0.001 0.50 (0.07) b0.001
0.47 (0.07) b0.001 0.39 (0.07) b0.001 0.52 (0.9) b0.001 4.60 (0.61) b0.001 0.74 (0.09) b0.001
0.05 (0.04) 0.18 0.02 (0.04) 0.052 0.16 (0.05) 0.004 0.60 (0.33) 0.07 0.27 (0.06) b0.001
0.12 (0.06) 0.03 0.14 (0.06) 0.022 0.22 (0.08) 0.007 1.73 (0.47) b0.001 0.49 (0.09) b0.001
0.01 (0.04) 0.80 0.001 (0.002) 0.67 −0.002 (0.004) 0.060 −0.02 (0.015) 0.25 −0.009 (0.003) 0.003
−0.30 (0.14) 0.040 −0.15 (0.09) 0.08 −0.79 (0.13) b0.001 −0.88 (0.49) 0.07 −0.15 (0.1) 0.12
−0.02 (0.02) 0.23 −0.13 (0.10) 0.17 −0.02 (0.02) 0.22 −0.14 (0.06) 0.03 −0.06 (0.11) 0.53
−0.62 (0.16) b0.001 −0.01 (002) 0.67 −0.24 (0.14) 0.09 −1.85 (0.54) b0.001 −0.04 (0.01) 0.001
3.54 (0.24) b0.001 4.57 (0.15) b0.001 3.85 (0.22) b0.001 23.18 (0.86) b0.001 4.33 (0.17) b0.001
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latter analysis was employed to estimate the odds ratios (OR) for achiev-
ing greater than 95% serum level between the two arms. Study centers
and participant number were included as random effects, and ﬁxed ef-
fects included age, gender, medication regimen, and time since seizure.
All statistical analyses were performed using SAS® software (Cary, NC,
USA).
3. Results
3.1. Demographic and baseline characteristics
The CONSORT ﬂow diagram shows 275 participants enrolled in the
study (Fig. 1). Three hundred patients were approached and checked
for eligibility. In total, two hundred and seventy-ﬁve patients were ran-
domized to receive intervention and standard care (Fig. 1). At follow-up,
4 patients (1.5%) did not return their questionnaires andwere not avail-
able for taking blood samples. Patients who dropped out were not sig-
niﬁcantly different from patients who completed the study. Clinical
and demographic characteristics between the two groups were com-
pared and did not differ from each other (Table 1).
3.2. Treatment integrity
TheMI qualitywas assessed usingMITI.Mean scores forMITI aswell
as SDs are shown in Table 2. There was evidence of adherence to the al-
located interventions. All MITI summary scores indicated a level of
achieving proﬁciency or competency (Table 2).
3.3. Primary outcomes
Tables 3 and 4 summarize the outcome measures over 6 months.
3.3.1. Medication adherence
Table 3 shows mean scores of MARS at baseline, 3 months, and 6
months in study groups. There was a progressive increase in average
MARS in the intervention group, but no change was observed in the
standard care group. Patients in the intervention group reported signif-
icantly higher medication adherence compared with those in the active
comparator group at 3 months (β=4.6, p b 0.001) and 6 months (β=
1.73, p b 0.001) of follow-ups.
3.3.2. Serum level
Table 5 shows results for estimating the serum level change over re-
peated visits. The odds ratios of serum level were increased by 1.35 in
patients in the intervention group (OR 1.35, 95% CIs: 1.07–1.71, p =
0.03) compared with those in the active comparator group at 3 monthsof follow-up. At the 6-month point, the chance of having patientswithin
reference range or higher were increased by 2.81 in patients in the in-
tervention group (OR 2.81, 95% CIs: 1.44–5.47, p = 0.002) compared
with those in the active comparator group.
3.3.3. Beliefs about medications
The mean change as well as SD of the BMQ-speciﬁc subscales are
shown in Table 3. Medication concerns reduced signiﬁcantly in patients
who received prescribed intervention in comparison with those in the
active control group at 3 and 6 months of follow-ups (p b 0.001)
(Table 5). Data on BMQ-necessity are shown in Tables 3 and 6. The MI
intervention group yielded a signiﬁcant increase in BMQ-necessity
versus the active comparator group at 3 and 6 months of follow-ups
(p b 0.001).
3.3.4. Social cognitive variables
There were some signiﬁcant differences between the groups on
the social cognitive variables at 3-month and 6-month follow-ups
(Tables 3, 6). In particular, patients in the intervention group reported
stronger intention and perceptions of control than patients in the active
comparator group for takingmedication regularly. Patients in the active
comparator group were less likely than patients in the intervention
group to report that they had a clear plan for takingmedication regular-
ly. In addition to this, patients in the active comparator group signiﬁ-
cantly reported lower levels of any plan to anticipate and overcome
barriers for taking medication regularly. Furthermore, self-monitoring
was signiﬁcantly improved in patients in the intervention group com-
pared with the patients in the active comparator group.
Changes in behavioral automaticity over time occurred in the inter-
vention group, and a signiﬁcant timeby group interaction indicated that
this was signiﬁcantly larger across time than in the active comparator
group. In the active comparator group, a nonsigniﬁcant decrease of
0.90 (SD = 0.39) over time was found.
3.3.5. Seizure severity
Over the 6-month follow-up, there was a statistically signiﬁcant dif-
ference between the intervention and the active comparator groups in
seizure severity (Tables 3, 7), with lower scores in the intervention
group (p b 0.05).
3.3.6. Health-related quality of life
At baseline, QOLIE-31 domain scores were generally well matched
between study groups (Tables 3 and 7). At 6 months, no signiﬁcant
changes from baseline in any domain were evident in the active com-
parator group. On the other hand, in patients receiving intervention,
the mean changes from baseline were statistically signiﬁcant in all do-
mains as well as the overall score (Table 7).
Table 7
Multiple linear regression models predicting health-related quality of life and seizure severity.
Variable Month SW OQOL EW EN/FA
Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value
Group (intervention vs. control) 14.75 (4.35) b0.001 11.62 (3.57) b0.001 6.00 (3.08) 0.05 14.58 (3.92) b0.001
Month 3 13.10 (1.98) b0.001 8.92 (1.61) b0.001 5.17 (1.35) 0.002 10.28 (1.81) b0.001
Intervention vs. control 3 14.75 (4.35) b0.001 9.53 (2.28) b0.001 7.50 (1.91) 0.001 11.71 (2.57) b0.001
Month 6 5.92 (1.68) 0.005 4.28 (1.33) 0.001 2.32 (0.099) 0.020 5.28 (1.37) b0.001
Intervention vs. control 6 6.57 (2.38) b0.001 4.75 (1.88) 0.01 3.57 (1.41) 0.019 5.57 (1.944) 0.004
Age −0.57 (0.14) b0.001 −0.67 (0.10) b0.001 −0.45 (0.09) b0.001 −0.79 (0.12) b0.001
Gender (male) 0.36 (0.34) 0.67 −4.18 (3.33) 0.21 −3.97 (3.13) 0.20 −9.98 (3.79) 0.008
Medication dosing regimens (monotherapy) −0.45 (0.39) 0.47 −0.89 (0.44) 0.04 2.82 (2.43) 0.41 −2.10 (0.50) b0.001
Time since seizure 1.88 (1.82) 0.71 −0.67 (0.10) b0.001 −1.65 (0.41) b0.001 −1.49 (1.17) 0.72
Intercept 101.97 (7.73) b0.001 69.51 (5.68) b0.001 98.50 (5.26) b0.001 90.93 (6.41) b0.001
Note SW= seizure worry, OQOL= overall quality of life, EW= emotional well-being, EN/FA= energy–fatigue, CF= cognitive functioning, ME=medication effects, SF = social func-
tioning, OS = Overall score, LSSS = Liverpool Seizure Severity Scale.
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Our results illustrate that at follow-up, patients in the intervention
group reported signiﬁcantly bettermedication adherence, stronger inten-
tion, and greater perceptions of control for taking medication regularly
compared with the active comparator group. Moreover, the intervention
group reported higher levels of action planning, coping planning, and
self-monitoring. Furthermore, we observed fewer medication concerns
and enhanced medication taking automaticity in patients who received
the intervention compared with the active comparator group.
As Gollwitzer points out, there are twophases for performing a given
behavior [42] such as adhering to medication: (1) the motivational
phase in which cognitions about the target behavior help patients to
make a decision to act (i.e., deciding to adhere to medication), and
(2) the volitional phase in which patients commit to act. According to
this conceptualization, the volitional phase reﬂects the implementation
of a patient's decisions. In this study, a combination of motivational and
volitional interventions were used in clinical practice to support pa-
tients with epilepsy in order to enhance their medication adherence.
Motivational interviewing is one form of a motivational intervention
which can help to facilitate decision-making in patients, while a voli-
tional intervention (including action planning, coping planning, and
self-monitoring) can help patients to commit themselves to change
behavior.
Motivational interviewing sessions stimulate a patient's self-
evaluation of readiness to change. It is important that the major factors
that have an impact on medication adherence be addressed in the pro-
cess of MI, such as beliefs about medication, the patient's concerns, and
relationshipwith the provider. For example, in a study byMcKenzie and
Chang [27], patients who initially described themselves as having poor
adherence and negative beliefs about taking medications were able to
improve their self-efﬁcacy, motivation to change, and medication
adherence.
It has been shown that MI can draw the participant's attention to-
wards reasons of poor medication adherence such as side effects. On
the other hand, MI seems effective in improving patients' motivation to
communicate these problems with their health-care provider [20,27].
For example, in a randomized controlled trial by Brown and Miller, it
was found that those patients who had a received MI became more mo-
tivated for medical adherence and also had a better prognosis [43].
Motivational interviewing is a technique which increases people's
motivation to adhere, but does not explicitly provide the skills to carry
out the steps needed for adherence. In contrast, volitional interventions
provide the skills needed to adhere but rely on participants already hav-
ing themotivation to adhere. The substantial improvement in adherence
seen in this study of our combined MI and volitional interventions is ev-
idence of the promise of using these two approaches together. It is neces-
sary to conduct additional similar studies in order to ﬁnd the best
combination of intervention components as well as the length andfrequency of such sessions in order to improve the efﬁciency and feasibil-
ity of MI interventions.
A large body of literature underscores the importance of family in-
volvement in illnessmanagement [44,45]. A pilot study, which included
caregivers in MI sessions for motivating asthma medication adherence
in adolescents [20], found that both caregivers and patients reported
higher adherence and quality of life. Therefore, future interventions
should consider explicitly incorporating family members or other social
supports into study designs and, in particular, intervention protocols
and outcome assessment in order to optimize approaches to improve
adherence and health outcomes for patients and those in their immedi-
ate social environment.
While this study showed greater adherence in the intervention
group than in the standard care group, the design did not allow for
the identiﬁcation of the most impactful component in the intervention.
Indeed, each of the elements of the intervention was included because
they were expected to contribute to greater adherence. Future research
could beneﬁt by identifying the components of the intervention which
have the strongest effects on adherence, as well as the beliefs or skills
which mediate the inﬂuence of those components on adherence. This
will allow reﬁnement of the intervention approach and reduce any un-
necessary or unhelpful content. Future studies should also investigate
whether a combination of MI with volitional interventions in other
groups of patients can improve medical adherence in other domains
such as diabetes or asthma.
In this study, the effectiveness of amultimodal intervention onmed-
ication adherence was assessed in a relatively short time (i.e., six
months). Future studies should also investigate longer term effective-
ness of this intervention on improving patients with epilepsy. Despite
this fact, the multimodal intervention had consistent and sizable effects
onmedication adherence aswell as patients' quality of life. Future stud-
ies are needed to investigate the effectiveness and cost-effectiveness of
this kind of intervention on medication adherence in other cultures. In
Iran, as a developing country, patients with epilepsy do not receive
any considerable intervention for their medication regimens. Neurolog-
ic clinics do not consider preventive care (i.e., medication adherence
and then seizure prevention) with the same emphasis as acute care.
On the other hand, Iranian patients often value attentive relationships
with their physicians. Therefore, they expect that their physicians
would spend more time listening to their health stories and discuss
their health problems in detail. The intervention described in the pres-
ent study provided an opportunity for patients in the intervention
group to build better relationships with their physicians, and patients
often received the intervention enthusiastically for this reason. More-
over, this study involved a patient's signiﬁcant others (i.e., family and
caregivers) to improve medication adherence for patients in the inter-
vention group. Thus, the involvement of family and caregivers also
synergized with the multimodal behavioral intervention in medication
adherence. Involving caregivers and health providers in MI sessions
Table 7
Multiple linear regression models predicting health-related quality of life and seizure severity.
CF ME SF OS LSSS
Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value Β (SE) p-Value
12.26 (4.92) 0.01 7.40 (4.72) 0.11 16.45 (2.95) b0.001 8.61 (3.12) 0.18 −14.02 (2.87) b0.001
12.81 (2.42) b0.001 8.92 (1.68) b0.001 11.75 (1.63) b0.001 13.39 (1.95) b0.001 −8.66 (1.51) b0.001
17.45 (3.42) b0.001 10.35 (2.38) b0.001 12.96 (2.31) b0.001 9.62 (2.47) 0.03 −10.84 (2.14) b0.001
3.90 (1.12) b0.001 3.21 (1.11) 0.004 3.14 (1.03) 0.002 3.09 (1.09) 0.008 −2.29 (1.20) 0.058
4.62 (1.59) b0.001 4.28 (1.57) 0.006 3.85 (1.46) 0.009 3.51 (1. 68) b0.001 −4.24 (1.70) b0.013
−0.62 (0.15) b0.001 −0.18 (0.14) 0.23 −0.46 (0.09) b0.001 −0.28 (0.05) 0.11 0.51 (0.08) b0.001
−10.71 (4.91) 0.03 −9.42 (4.93) 0.056 3.66 (2.85) 0.200 −3.31 (2.85) 0.006 1.60 (1.30) 0.54
−0.48 (0.65) 0.45 −0.44 (0.41) 0.500 −4.17 (3.12) 0.18 −3.71 (3.24) 0.12 0.56 (0.34) 0.10
7.12 (5.39) 0.188 −14.68 (5.40) 0.007 −1.61 (0.37) b0.001 −1.01 (0.21) 0.25 5.40 (2.88) 0.06
67.37 (8.27) b0.001 63.35 (8.23) b0.001 89.93 (4.83) b0.001 72.83 (6.71) b0.001 61.22 (4.50) b0.001
141A.H. Pakpour et al. / Epilepsy & Behavior 52 (2015) 133–142could be beneﬁcial in terms of providing support for the patient and fa-
cilitating communications over concerns and uncertainties towards
prescriptions, thus, improving adherence todrug regimens. Future stud-
ies should investigate the exact role of a patient's signiﬁcant others and
the physician–patient relationship in improving medication adherence
in patients with epilepsy.
4.1. Conclusion
In conclusion, this study shows that the provision of an intervention
based on motivational interviewing can signiﬁcantly improve the med-
ication adherence of patients with epilepsy, and points to the value of
such an intervention for medication adherence in general.
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